tbuckley/cabot-search huggingface dataset:
Leptomeningeal dissemination from primary brainstem tumors in the adults: A retrospective analysis of 128 cases.
Authors: M. Passarin, R. Pedersini, B. Masotto, E. Vattemi, T. Fasano, M. Gabaldo, E. Buffone, C. Ghimenton, E. Gilioli, S. Turazzi
Journal: Journal of Clinical Oncology (2010)

e12533 Background: Primary brainstem tumors (PBST) are the most common neoplasm of central nervous system (CNS) in children. In adults PBST is a rare disease, the incidence was reported to be 5% of CNS primary tumors. Leptomeningeal dissemination (LD) of PBST through the cerebrospinal fluid (CSF) pathway frequently described in childhood is a rare event in adult patients (pts). Methods: In this study we analyzed retrospectively 128 consecutive pts with PBST who referred to the Neurosurgery Department of Verona Hospital ( Italy) between 1998 to 2008. Tumor locations were as follows: mesencephalic area in 25% of the pts, pont in 23%, bulbar region in 45% and bulbar-cervical junction in 6,2%. The histology were: gliomas in 58% of the pts, ependymoma in 22% and other histologic type in 20%. Results: LD was diagnosed in 4.7 % of pts with PBST (6/128), occurring in 2 pts with glioblastoma and 4 pts with grade II astrocitoma. All pts with LD were male, median age was 38 years (28-42), median KPS was 80 (80-100). Radical surgery of primary tumor has been performed in 2 patients, while 4 patients received a subtotal resection. 66% (4/6) of patients have received radiotherapy as treatment of primary tumor and 33% (2/6) received chemotherapy. Median time to LD was 24 months for all patients with PBST. Low-grade tumors had a longer median time to dissemination than high grade tumors (19 vs. 24 months) and patients with gross total resection had longer median time to dissemination than patients with subtotal resection (24 vs. 19 months). Treatment of LD was as follow: 3 patients (33%) received sistemic chemotherapy with temozolomide, 1 patient (16%) received intrathecal chemotherapy with ARA-C, 1 patient (16%) received intrathecal chemotherapy with thiotepa, 1 patient (16%) received a combination of sistemic temozolomide and intrathecal ARA-C and 1 patient received no treatment. Median OS of patients with LD was 24 weeks. Conclusions: In this study we found out a correlation between LD and histologic grading of the tumors, radicality of surgery, therapeutic approaches. Moreover, the treatment of LD had partially modified the evolution of this disease and permitted a better quality of life and good control of the symptoms in patients. No significant financial relationships to disclose.
Novel Fc-Engineered Anti-B Cell Maturation Antigen-Monomethyl Auristatin F Antibody-Drug Conjugate (GSK2857916) Induces Potent and Selective Anti-Multiple Myeloma Activity Via Enhanced Effector Function and Direct Tumor Cell Killing
Authors: Yu-Tzu Tai, Chirag Acharya, Mike Y Zhong, Michele Cea, Antonia Cagnetta, Patrick A Mayes, Jenny L Craigen, Louise Gliddon, James Smothers, Amanda L Christie, Andrew L. Kung, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood (2013)
TCT-803 Twelve-month Clinical Outcomes of Peripheral Arterial Disease Patients with or without Critical Limb Ischemia undergoing Percutaneous Transluminal Angioplasty
Authors: Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Jin oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2015)
CA184-156: A randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus EP in subjects with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC).
Authors: David R. Spigel, Christoph Zielinski, Sabine Maier, Veerle de Pril, Justin P. Fairchild, Jean-Marie Cuillerot, Martin Reck
Journal: Journal of Clinical Oncology (2012)

TPS7113 Background: EP (4-6 cycles) is standard of care 1st-line therapy for metastatic SCLC, and no multinational studies have reported any improvement beyond that reported for EP. Evidence of an ongoing immune response to SCLC tumors suggests that immunotherapy that enhances this immune response to SCLC may enhance the clinical benefit of EP. Ipi, a fully human monoclonal antibody which blocks CTLA-4, augments antitumor immune responses. Because some responses to Ipi may differ from those observed with cytotoxic therapies, immune-related response criteria (irRC) were derived from WHO criteria to better capture response patterns observed with Ipi. A randomized Phase 2 study of Ipi with paclitaxel/carboplatin (PC) in pts with ED-SCLC showed significant improvement in progression-free survival (PFS), as measured by irRC, over PC alone in pts receiving Ipi and PC in a phased regimen (Ipi started after 2 cycles of PC). Furthermore, addition of Ipi did not exacerbate PC toxicity, and immune-related adverse events were managed using protocol-specific guidelines. This multicenter phase III study in pts with ED-SCLC (ClinicalTrials.gov identifier NCT01450761) will determine whether adding Ipi to EP increases OS vs EP alone. Methods: EP consists of 4 cycles of etoposide (100 mg/m 2 , IV on Days 1-3 every 3 weeks [Q3W]) and cisplatin (75 mg/m 2 , IV) or carboplatin (AUC=5, IV) once Q3W. Pts will be randomized to receive 4 doses of Ipi (10 mg/kg, IV) in Arm A or placebo in Arm B, Q3W during induction, starting after 2 cycles of EP (phased schedule). Eligible pts will then receive blinded study drug (Ipi in Arm A; placebo in Arm B) Q12W until disease progression or unacceptable toxicity. The primary objective is to compare OS. Secondary objectives are to compare OS in those who receive blinded study drug, compare PFS between study arms, and to estimate best overall response rate and duration of response. First-line ED-SCLC pts with ECOG performance ≤1 will be included. Pts with symptomatic CNS metastases or a history of autoimmune disease will be excluded. The study will randomize 1100 pts at a 1:1 ratio.
Pattern recognition receptors in zebrafish provide functional and evolutionary insight into innate immune signaling pathways
Authors: Yajuan Li, Yuelong Li, Xiaocong Cao, Xiangyu Jin, Tengchuan Jin
Journal: Cellular and Molecular Immunology (2016)

Pattern recognition receptors (PRRs) and their signaling pathways have essential roles in recognizing various components of pathogens as well as damaged cells and triggering inflammatory responses that eliminate invading microorganisms and damaged cells. The zebrafish relies heavily on these primary defense mechanisms against pathogens. Here, we review the major PRR signaling pathways in the zebrafish innate immune system and compare these signaling pathways in zebrafish and humans to reveal their evolutionary relationship and better understand their innate immune defense mechanisms.
TCT-630 Transfemoral aortic valve implantation (TAVI) with the balloon-expandable Edwards Sapien 3 valve compared with the self-expanding Medtronic CoreValve
Authors: Julia Seeger, Birgid Gonska, Christoph Rodewald, Dominik Scharnbeck, Sinisa Marcovic, Wolfgang Rottbauer, Jochen Wöhrle
Journal: Journal of the American College of Cardiology (2015)
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Authors: Etienne Dardenne, Himisha Beltran, Matteo Benelli, Kaitlyn Gayvert, Adeline Berger, Loredana Puca, Joanna Cyrta, Andrea Sboner, Zohal Noorzad, Theresa MacDonald, Cynthia Cheung, Ka Shing Yuen, Dong Gao, Yu Chen, Martin Eilers, Juan-Miguel Mosquera, Brian D. Robinson, Olivier Elemento, Mark A. Rubin, Francesca Demichelis, David S. Rickman
Journal: Cancer Cell (2016)
ABL Mutations in Late-Chronic Phase Chronic Myeloid Leukemia Patients with Cytogenetic Refractoriness to Imatinib Are Associated with a Greater Likelihood of Progression to Blast Crisis and Shorter Survival. on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia.
Authors: Simona Soverini, Giovanni Martinelli, Gianantonio Rosti, Simona Bassi, Marilina Amabile, Angela Poerio, Barbara Giannini5, Elena Trabacchi, Emanuela Ottaviani, Tiziana Grafone, Carolina Terragna, Matteo Renzulli, Nicoletta Testoni, Simona Luatti, Fausto Castagnetti, Daniela Cilloni, Milena Fava, Barbara Izzo, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani
Journal: Blood (2004)
PET-Based Textural Analysis Assessment in Early Stage Hodgkin Lymphoma Treated with Standard Combined Approach
Authors: Angelo Fama, Patrizia Ciammella, Massimiliano Casali, Elisa Barbolini, Ala Podgornii, Mauro Iori, Annibale Versari, Franceso Merli, Giacomo Feliciani
Journal: Blood (2015)
Abstract LB-088: Ptch1 heterozygosity predisposes mice to developing IR-induced BCCs
Authors: Grace Y. Wang, Eileen Libove, Danielle Tucker, Ervin Epstein
Journal: Cancer Research (2015)

Abstract Basal cells nevus syndrome (BCNS, Gorlin syndrome) patients carry heterozygous germline mutations in PATCHED1 (PTCH1) gene, which encodes a receptor of hedgehog (HH) ligands and represses HH signaling in the absence of ligands. Mutated PTCH1 leads to aberrant activation of the HH signaling pathway, which is the pivotal driver underlying BCC carcinogenesis in both sporadic and BCNS BCCs. BCNS (PTCH1+/-) individuals are very susceptible to developing more BCCs at an earlier age but the mechanism for this genetic predisposition to BCCs remains elusive. In this study, we assessed how heterozygosity of the murine Ptch1 gene contributes to IR-induced BCC carcinogenesis. Specifically, we treated Ptch1fl/+ K14CreER2 mice with tamoxifen either at age 4 weeks (group A) or at 9 weeks (group B) to delete one copy of Ptch1 in K14-expressing keratinocytes. We irradiated both groups of mice with IR at mouse age 8 weeks so that at the time of IR, keratinocytes in group A mice, like those in BCNS patients, were Ptch1+/-, and mice in group B remained Ptch1+/+ but subsequent to recovery from acute damage all mice had Ptch1+/- keratinocytes. We found that mice in both groups developed similar amounts of microscopic BCCs at age either 7- or 9-months. However, only mice of group A (3 out of 13 mice) developed visible BCCs; none of the mice of group B (n = 30) developed visible BCCs by age 18-months, the longest time point monitored based on our studies of Ptch1+/- mice. The difference is statistically significant (p = 0.03). Histologically, these visible BCCs closely resemble human BCCs. This finding indicates (i) that heterozygosity of the Ptch1 gene limited to keratinocytes (without gene deletion in stromal cells) is sufficient to produce susceptibility to IR-induced visible BCC development and (ii) surprisingly that heterozygosity of the Ptch1 gene during acute mutagenic damage dramatically increases eventual conversion of microscopic to visible BCCs, probably by affecting acute repair of this damage. To gain further insights into this possible mechanism, we are culturing keratinocytes from these mice and performing cell cycle and apoptosis analysis upon IR treatment in vitro. Citation Format: Grace Y. Wang, Eileen Libove, Danielle Tucker, Ervin Epstein. Ptch1 heterozygosity predisposes mice to developing IR-induced BCCs. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-088. doi:10.1158/1538-7445.AM2015-LB-088
TCT-58 Immediate and long-term outcomes of ischemic versus non-ischemic functional mitral regurgitation in patients treated with MitraClip: insights from the 2011-12 Pilot European Sentinel Registry of Percutaneous Edge-to-Edge Mitral Valve Repair
Authors: Michele Pighi, Rodrigo Estevez-Loureiro, Francesco Maisano, Gian Paolo Ussia, Gianni Dall'Ara, Olaf Franzen, Reidar Winter, Georg Nickenig, Martine Gilard, Carlo Di Mario
Journal: Journal of the American College of Cardiology (2015)
Adapting Cyclosporine to Calcineurin Activity Rather Than to Cyclosporine Blood Levels: Toward a Functional Management of Graft-Versus-Host Disease Prophylaxis.
Authors: Sylvia Sanquer, Sebastien Maury, Yosr Hicheri, Elvira Martin, Marie Robin, Cecile Pautas, Robert Barouki, Gerard Socie, Mathieu Kuentz, Catherine Cordonnier
Journal: Blood (2007)
TCT-790 Safety and Effectiveness of the Nav-6 Filter in Preventing Distal Embolization during JetStream Atherectomy of Infrainguinal Peripheral Artery Lesions
Authors: Avantika Banerjee, Karan Sarode, Atif Mohammad, Emmanouil Brilakis, Gail A. Shammas, Nicolas W. Shammas
Journal: Journal of the American College of Cardiology (2015)
TCT-477 Normalized Troponin Increase to Area at Risk for Procedural Myonecrosis Assessment and Prognostication After Percutaneous Coronary Intervention in Coronary Bifurcation Lesions – Insights From Intracoronary Electrocardiography Based Strategy for the Treatment of Coronary Bifurcation Lesions.
Authors: Dobrin Vassilev, Kiril Karamfiloff, Lyubomir Dosev, Jivka Stoykova, Svetoslav Stoimenov, Margarita Jekova, Vladimir Naunov, Ralica Pancheva, Robert J. Gil
Journal: Journal of the American College of Cardiology (2015)
Survival and Risk of Leukemic transformation in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study on 1,104 Patients
Authors: Tiziano Barbui, Juergen Thiele, Francesco Passamonti, Elisa Rumi, Emanuela Boveri, Marco Ruggeri, Francesco Rodeghiero, Emanuele D'Amore, Maria Luigia Randi, Irene Bertozzi, Filippo Marino, Alessandro M. Vannucchi, Elisabetta Antonioli, Valentina Carrai, Heinz Gisslinger, Veronika Buxhofer-Ausch, Leonhard Müllauer, Alessandra Carobbio, Andrea Gianatti, Naseema Gangat, Curtis A. Hanson, Ayalew Tefferi
Journal: Blood (2010)
Randomized phase III study of high-dose sequential chemotherapy (CT) supported by peripheral blood progenitor cells (PBPC) for the treatment of small cell lung cancer (SCLC): Results of the EBMT Random-ICE trial
Authors: S. Leyvraz, S. Pampallona, G. Martinelli, F. Ploner, S. Aversa, G. Rosti, P. Brunsvig, A. Montes, U. Yilmaz, L. Perey
Journal: Journal of Clinical Oncology (2006)

7064 Background: EBMT has defined in a phase II trial (JCO 1999, 3531) feasibility and activity of high-dose sequential CT for SCLC increasing 3 fold the dose-intensity and significantly the peak-dose and the total dose of CT. Methods: Randomized prospective study aiming to improve the 3-year survival from 12% in the standard (S) to 24% in the high-dose (H) arm, for a total accrual of 340 patients. Limited or extensive ≤ 2 metastatic sites, age ≤ 65 y.o., PS 0–1. Arm S/Arm H: ifosfamide 5 g/m 2 d1/2.5 g/m 2 /d × 4; carboplatin 300 mg/m 2 d1/AUC = 5/d × 4; etoposide 180 mg/m 2 /d. × 2/300 mg/m 2 /d × 4, every 28 days, for 6 cycles in Arm S. Three cycles were given in Arm H supported by PBPC collected after 2 courses of epirubicin 150 mg/m 2 /paclitaxel 175 mg/m 2 . Due to low accrual, a formal stopping rule was introduced with boundaries for early stopping in favour of a difference (O’Brien-Fleming) or of lack thereof (Pocock). The present analysis has been done with 110 deaths. Results: Since June 1997, 145 patients have been accrued (evaluable =140, S = 71, H = 69), median age 53, prognostic factors balanced. Mobilization toxicity ≥ 3: neutropenia 61%, thrombopenia 11%, anemia 7%, infection 6%, mucositis 9% and 2 toxic deaths. Toxicity ≥ 3 among 353 cycles of S and 152 of H respectively: neutropenia 26%/100%, thrombopenia 12%/100%, anemia 8%/69%, infection 1%/15%, fever 11%/72%, toxic death 1/8. Response rate of S and H: 67% (CR 32%)/77% (CR 37%) (p = 0.188). Median follow-up 4.9 years. Progression free survival 8.8 and 12 months (p = 0.737, unadjusted) and median overall survival 15 and 19.1 months (p = 0.659, unadjusted) for S and H respectively. At 3 years, 19% of the patients were alive in both arms. Conclusions: Random-ICE was designed with strong statistical power and shows no evidence that the treatment of SCLC can be improved by increasing the dose-intensity, the peak-dose or the total dose of ICE and that such intensification strategy should probably be abandoned. No significant financial relationships to disclose.
Statins Impair Antitumor Effects of CD20 mAb by Inducing Conformational Changes of CD20.
Authors: Jakub Golab, Magdalena Winiarska, Jacek Bil, Ewa Wilczek, Grzegorz Wilczynski, Malgorzata Lekka, Patrick J. Engelberts, Wendy J.M. Mackus, Tomasz Stoklosa, Dominika Nowis, Marcin Makowski, Eliza Glodkowska, Tadeusz Issat, Piotr Mrowka, Witold Lasek, Elzbieta Gorska, Maria Wasik, Krzysztof Warzocha, Maciej Sinski, Zbigniew Gaciong, Anna Dabrowska-Iwanicka, Marek Jakobisiak, Paul W.H.I. Parren
Journal: Blood (2007)
TCT-303 Diagnostic Performance of Instantaneous Wave-Free Ratio for Physiological Assessment of Coronary Stenosis Severity: A Bivariate Meta-analysis
Authors: Alok Saurav, Aiman Smer, Venkata M. Alla, Michael D. White, Ruby Satpathy, Manu Kaushik, Mark Woodruff, Michael DelCore, Aryan Mooss
Journal: Journal of the American College of Cardiology (2015)
Serum Evaluation of a Panel of 10 Cytokines in Patients with Follicular Lymphoma: High Serum Level of TGF-β Correlates with Good Prognosis, Independently of the FLIPI Score.
Authors: Herve Ghesquieres, Sana Intidhar Labidi, Christine Caux, Sylvie Chabaud, Therese Gargi, Catherine Chassagne, Catherine Sebban, Pierre Biron, Jean-Yves Blay
Journal: Blood (2007)
Correlation between Tumor Uptake on Indium-111 Ibritumomab Tiuxetan Imaging and Size on CT to Disease Response on FDG PET/CT Scans Obtained Pre- and Post-Yttrium-90 Ibritumomab Tiuxetan Therapy for Non-Hodgkin Lymphoma.
Authors: Jacob M. Alexnder, Judith M. Joyce, Barry M. McCook, Norbert Avril, Stephanie R. Land, Mirsada Begovic, Samuel A. Jacobs
Journal: Blood (2005)
Asymptomatic Cobblestoned Plaques on the Soles
Authors: Bahram Razani, Jeffrey North, Rachel Kornik
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
A phase I study of chemo-radiotherapy using gemcitabine as a radiosensitiser in patients with metastases to the brain
Authors: J. Sgouros, S. Upadhyay, M. Braun, M. Holmes, A. Maraveyas
Journal: Journal of Clinical Oncology (2004)

1570 Background: Conventional treatment for patients with brain metastases is whole-brain radiotherapy (WBRT). Efficacy is poor and median survival for these patients is 2–3 months. One way to increase the efficacy of radiotherapy (RT) is to use a radiosensitising agent. Gemcitabine (gem) is a potent radiosensitiser. There is also some evidence that it crosses the blood-brain barrier. The primary objective of this study was to determine the maximum tolerated dose (MTD) of gem when given in conjunction with WBRT. Methods: Patients with brain metastases and fit for RT were included in the study. Adequate haematological, renal and liver functions and clinical stability on steroids were required. WBRT was 30Gy in 10 daily fractions. Gem was given 2–4 hours prior to RT on day 1 and 8 of the first cohort of patients and then day 1, 4, 8 and 11 subsequently. Starting dose was 25mg/m2, escalated by 12.5mg/m2increments. At least 3 patients were included per level. Dose limiting toxicity (DLT) was defined as grade 4 haematological toxicity or grade ≥ 3 non-haematological toxicity. Results: 25 patients were entered in the study. 15 male, 10 female. 74% had a PS 1 (WHO). Twelve had NSCLC, 6 colorectal, 4 breast cancer, 2 renal cell carcinoma and 1 oesophageal carcinoma. 92% had concurrent extracranial disease. Six had a single brain metastasis, 13 had 2 or 3 metastases and 6 multiple. Up to 50mg/m2 (level 4) no DLT was observed but at this level 6 out of 7 patients had at least one dose reduced or omitted due to toxicity. At level 5 (62.5mg/m2) and at level 6 (75mg/m2) 1 out of 6 and 1 out of 2 patients developed DLT (thrombocytopenia-bleeding and neutropenic sepsis).Conclusions: The MTD of gem in this schedule is 62.5mg/m2. A phase II study evaluating the efficacy of the regime has commenced. No significant financial relationships to disclose.
Growth Factor Independent 1b (Gfi1b) Is Highly Expressed in Human CML and Accelerates p210BCR-ABL Induced Leukemia in Mice.
Authors: Lothar Vassen, Daniel G. Tenen, Bert A. van der Reijden, Ulrich Duehrsen, Tarik Moroy, Stefan Mahlmann, Peter Ebeling, Joop H. Jansen
Journal: Blood (2007)
TCT-345 Detailed Segmental Comparison Between a Dedicated Bifurcation Stent and Balloon Angioplasty Using Intravascular Ultrasound and Three-dimensional Quantitative Coronary Angiography: a Subgroup Analysis of the Tryton IDE Randomized Trial
Authors: Maik J. Grundeken, Hector Manuel Garcia Garcia, Maciej Lesiak, Pieter R. Stella, Imre Ungi, Linn L. Laak, Philippe Genereux, Aaron Kaplan, Martin Leon, Joanna J. Wykrzykowska, Yoshinobu Onuma, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2015)
Genetic Evidence for a Predominant Role of PI3Kβ In ITAM— and Integrin-Mediated Signaling in Platelets
Authors: Ilaria Canobbio, Lucia Stefanini, Lina Cipolla, Elisa Ciraolo, Cristian Gruppi, Emilio Hirsch, Cesare Balduini, Mauro Torti
Journal: Blood (2008)
TCT-427 Safety and Efficacy of The ProStar XL Percutaneous Vascular Closure System for Transfemoral Transcatheter Aortic Valve Replacement (TAVR): a Single Center Six-year Experience
Authors: Roberta Serdoz, Alistair C. Lindsay, Alison Duncan, Araan Daqa, Simon Daves, Ismail D. Kilic, Enrico Fabris, Gianluca Caiazzo, Francesco Romeo, Carlo Di Mario, Neil Moat
Journal: Journal of the American College of Cardiology (2015)
Patterns of B Cell Activating Factor (BAFF) Levels, B Cell Recovery, and BAFF/B Cell Ratios Correlate with the Development of Chronic Graft-Versus-Host Disease (cGVHD) Following Hematopoietic Stem Cell Transplantation (HSCT)
Authors: Caron A. Jacobson, Haesook T Kim, Stefanie Sarantopoulos, Lixian Sun, Sean McDonough, Carol G Reynolds, Maria I. Herrera, John Koreth, Corey S. Cutler, Vincent T Ho, Edwin P Alyea, Philippe Armand, Robert J. Soiffer, Joseph H. Antin, Jerome Ritz
Journal: Blood (2011)
TCT-810 “The Phantom Streamlinear” as a Therapeutic Option in the Management of Total Body Thoraco-abdominal Aortic Pathology[TAAA]. Early Results.
Authors: Sherif Sultan, Victor Costache, Ala Elhelali, Edel P. Kavanagh, Mohammed Sultan, Florian Stefanov, Violet Lundon, Niamh Hynes
Journal: Journal of the American College of Cardiology (2015)